{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:14:36Z","timestamp":1790871276651,"version":"4.1.0"},"reference-count":79,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,9,19]],"date-time":"2007-09-19T00:00:00Z","timestamp":1190160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Cellular Biochemistry"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Two primary reasons explain its aggressive behavior: most patients present with advanced disease at diagnosis, and die of recurrences from disease that has become resistant to conventional chemotherapies. In this paper on epithelial ovarian cancer (EOC), we will review molecular alterations associated with the few precursor lesions identified to date, followed by the more commonly recognized processes of de novo carcinogenesis, metastasis, and the development of chemoresistance. We will propose a unifying model of ovarian epithelial tumorigenesis that takes into account various hypotheses. We will also review novel approaches to overcome the major problem of chemoresistance in ovarian cancer. Finally, we will discuss advances and new challenges in the development of mouse model systems to investigate EOC precursor lesions, progression, metastasis, and chemoresistance. J. Cell. Biochem. 102: 1117\u20131129, 2007. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jcb.21552","type":"journal-article","created":{"date-parts":[[2007,9,19]],"date-time":"2007-09-19T11:27:47Z","timestamp":1190201267000},"page":"1117-1129","source":"Crossref","is-referenced-by-count":43,"title":["Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer"],"prefix":"10.1002","volume":"102","author":[{"given":"Jeremy R.","family":"Chien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Aletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra A.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Keeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viji","family":"Shridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn C.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,9,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.2002.20.4.1147","article-title":"Ovarian and papillary\u2010serous peritoneal carcinoma: Pilot study with thalidomide","volume":"20","author":"Abramson N","year":"2002","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(02)02315-8"},{"key":"e_1_2_10_4_1","first-page":"2063","article-title":"Transformation of cultured rat ovarian surface epithelial cells by Kirsten murine sarcoma virus","volume":"41","author":"Adams AT","year":"1981","journal-title":"Cancer Res"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1123"},{"key":"e_1_2_10_6_1","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies","volume":"8","author":"Aghajanian C","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61196-8"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3931"},{"key":"e_1_2_10_9_1","first-page":"3466","article-title":"Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays","volume":"62","author":"Bayani J","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800306"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603509"},{"key":"e_1_2_10_12_1","first-page":"426","article-title":"Advances in the management of epithelial ovarian cancer","volume":"50","author":"Berkenblit A","year":"2005","journal-title":"J Reprod Med"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/418823a"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2566"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.10.874"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04296"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.23.9018-9027.2000"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.104"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr051024"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.5009"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.091"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.8.510"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1230"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1258\/136218006777525794"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2006.09.026"},{"key":"e_1_2_10_26_1","first-page":"1389","article-title":"Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer","volume":"63","author":"Connolly DC","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0b013e328011a21f"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1173"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.3743"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5275"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000088479"},{"key":"e_1_2_10_32_1","first-page":"3459","article-title":"Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium","volume":"63","author":"Flesken\u2010Nikitin A","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2006.01960.x"},{"key":"e_1_2_10_34_1","first-page":"455s","article-title":"Interim report of a phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian and primary peritoneal carcinoma: A California Cancer Consortium trial","volume":"23","author":"Garcia AA","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2005.03.019"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2005.00137.x"},{"key":"e_1_2_10_37_1","first-page":"4280","article-title":"Spontaneous malignant transformation of human ovarian surface epithelial cells in vitro","volume":"7","author":"Gregoire L","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_10_38_1","first-page":"141","article-title":"Phase I study of flavopiridol 24 hour infusion monotherapy in solid tumours (HMR1275\/1002)","volume":"22","author":"Gries JM","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004347-199904000-00010"},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/jco.2004.22.90140.3058","article-title":"A phase I trial of gemcitabine, 17\u2010allylaminogeldanamycin and cisplastin in solid tumour patients","volume":"22","author":"Haluska P","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1673"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63306-8"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204091"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.136"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2004.02.006"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2682"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(00)00191-1"},{"issue":"1","key":"e_1_2_10_49_1","first-page":"202a","article-title":"A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC\u2010PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum","volume":"21","author":"Joly F","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00660.x"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2091"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1290\/1071-2690(2001)037<0515:DAGPOH>2.0.CO;2"},{"key":"e_1_2_10_53_1","volume-title":"Cancer medicine.","author":"Liotta LA","year":"2005"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3380"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0736"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-005-1838-3"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4490"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(11)91579-8"},{"key":"e_1_2_10_59_1","first-page":"6059","article-title":"Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid","volume":"51","author":"O'Dwyer PJ","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.249"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00335-002-4003-4"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(01)00002-2"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(02)00144-0"},{"key":"e_1_2_10_64_1","first-page":"4656","article-title":"Intraperitoneal therapy of ovarian cancer using an engineered measles virus","volume":"62","author":"Peng KW","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.05358"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.4.585"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.264"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0462"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63708-X"},{"key":"e_1_2_10_70_1","first-page":"5895","article-title":"Genetic analysis of early\u2010 versus late\u2010stage ovarian tumors","volume":"61","author":"Shridhar V","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.6.484"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.9363"},{"key":"e_1_2_10_73_1","first-page":"203","article-title":"Final report of the phase I clinical program of the novel raf kinase inhibitor BAY 43\u20109006 in patients with refractory solid tumours","volume":"22","author":"Strumberg D","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1984"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603672103"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.04.036"},{"key":"e_1_2_10_77_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/jco.2004.22.90140.3060","article-title":"A phase I pharmacokinetic study of HGS\u2010ETR1 (TRM1), a human monoclonal against\u2010antibody to TRAIL\u2010R1, in patients with advanced solid tumours","volume":"22","author":"Tolcher AW","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21969"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502256102"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.4.8.1869"}],"container-title":["Journal of Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcb.21552","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcb.21552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:31:19Z","timestamp":1697157079000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcb.21552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,19]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1002\/jcb.21552"],"URL":"https:\/\/doi.org\/10.1002\/jcb.21552","archive":["Portico"],"relation":{},"ISSN":["0730-2312","1097-4644"],"issn-type":[{"value":"0730-2312","type":"print"},{"value":"1097-4644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,19]]}}}